PPARy AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE
Methods of treatment of Huntington's disease or its symptoms, with PPARγ agonists, and in particular, the compound of formula (I) known as INT131:
1 . A method of treating Huntington's disease in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
2 . A method of treating the symptoms of Huntington's disease in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
3 . The method of claim 1 , wherein the compound of formula (I), a pharmaceutically acceptable salt, prodrug, or isomer thereof is given prophylactically.
4 . The method of claim 3 , wherein onset of Huntington disease signs and symptoms are delayed.
5 . The method of any one of claims 1 to 2 , wherein the compound of formula (I) is in the form of a besylate salt.
6 . The method of any one of claims 1 to 2 , wherein the therapeutically effective amount is from about 0.1 to about 15 milligrams.
7 . The method of claim 6 , wherein the therapeutically effective amount is from about 1 to about 10 milligrams.
8 . The method of claim 7 , wherein the therapeutically effective amount is from about 2 to about 6 milligrams.
9 . The method of claim 8 , wherein the therapeutically effective amount is about 3 milligrams.
10 . The method of any one of claims 1 to 2 , wherein the pharmaceutical composition is administered to the subject twice a day, daily, every other day, three times a week, twice a week, weekly, every other week, twice a month, or monthly.
11 . The method of claim 10 , wherein the pharmaceutical composition is administered to the subject daily.
12 . The method of any one of claims 1 to 2 , wherein the pharmaceutical composition is administered to the subject daily and the therapeutically effective amount of the compound is about 3 milligrams.
13 . The method of any one of claims 1 to 2 , wherein the method provides an increase in adiponectin level in the subject by at least about 30%, at least about 68%, at least about 175%, or at least about 200%.
14 . The method of claim 13 , wherein the increase is by at least about 175%.
15 . The method of any one of claims 1 to 2 , wherein the method does not result in an increase in adipocytes or adipose tissue.
16 . The method of any one of claims 1 to 2 , wherein glucose metabolism in brain cells is increased.
17 . The method of any one of claims 1 to 2 , wherein glucose metabolism in adipose tissue is increased.
18 . The method of any one of claims 1 to 2 , wherein the lifespan of the subject is longer than the lifespan of a subject with Huntington's disease not administered the compound of formula (I), a pharmaceutically acceptable salt, prodrug, or isomer thereof.
19 . The method of any one of claims 1 to 2 , wherein the metabolic dysregulation in the subject is reduced.
20 . The method of any one of claims 1 to 2 , wherein the subject's appetite is increased.
21 . The method of any one of claims 1 to 2 , wherein the weight loss in the subject is reduced.
22 . The method of any one of claims 1 to 2 , wherein insulin resistance in the subject is reduced.
23 . A method of treating Huntington's disease in a subject in need thereof comprising increasing adiponectin levels in the subject, wherein adiponectin levels are increased by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
24 . A method of treating the symptoms of Huntington's disease in a subject in need thereof comprising increasing adiponectin levels in the subject, wherein adiponectin levels are increased by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
25 . The method of claim 23 , wherein the compound of formula (I), a pharmaceutically acceptable salt, prodrug, or isomer thereof is given prophylactically.
26 . The method of claim 25 , wherein onset of Huntington disease signs and symptoms are delayed.
27 . The method of any one of claims 23 to 24 , wherein the compound of formula (I) is in the form of a besylate salt.
28 . The method of any one of claims 23 to 24 , wherein the therapeutically effective amount is from about 0.1 to about 15 milligrams.
29 . The method of claim 28 , wherein the therapeutically effective amount is from about 1 to about 10 milligrams.
30 . The method of claim 29 , wherein the therapeutically effective amount is from about 2 to about 6 milligrams.
31 . The method of claim 30 , wherein the therapeutically effective amount is about 3 milligrams.
32 . The method of any one of claims 23 to 24 , wherein the pharmaceutical composition is administered to the subject twice a day, daily, every other day, three times a week, twice a week, weekly, every other week, twice a month, or monthly.
33 . The method of claim 32 , wherein the pharmaceutical composition is administered to the subject daily.
34 . The method of any one of claims 23 to 24 , wherein the pharmaceutical composition is administered to the subject daily and the therapeutically effective amount of the compound is about 3 milligrams.
35 . The method of any one of claims 23 to 24 , wherein the adiponectin level in the subject is increased by at least about 30%, at least about 68%, at least about 175%, or at least about 200%.
36 . The method of claim 35 , wherein the increase is by at least about 175%.
37 . The method of any one of claims 23 to 24 , wherein the method does not result in an increase in adipocytes or adipose tissue.
38 . The method of any one of claims 23 to 24 , wherein glucose metabolism in brain cells is increased.
39 . The method of any one of claims 23 to 24 , wherein glucose metabolism in adipose tissue is increased.
40 . The method of any one of claims 23 to 24 , wherein the lifespan of the subject is longer than the lifespan of a subject with Huntington's disease not administered the compound of formula (I), a pharmaceutically acceptable salt, prodrug, or isomer thereof.
41 . The method of any one of claims 23 to 24 , wherein the metabolic dysregulation in the subject is reduced.
42 . The method of any one of claims 23 to 24 , wherein the subject's appetite is increased.
43 . The method of any one of claims 23 to 24 , wherein the weight loss in the subject is reduced.
44 . The method of any one of claims 23 to 24 , wherein insulin resistance in the subject is reduced.